---
document_datetime: 2025-01-07 15:34:08
document_pages: 26
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/increlex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: increlex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 15.5304012
conversion_datetime: 2025-12-28 12:24:09.671145
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Increlex

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|---------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| IA/0086              | A.7 - Administrative change - Deletion of manufacturing sites | 06/01/2025                          |                                             | Annex II and PL                  |                                   |
| S/0083               | Annual re-assessment.                                         | 12/12/2024                          | n/a                                         |                                  |                                   |
| PSUSA/1942/          | Periodic Safety Update EU Single assessment -                 | 11/04/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| 202308             | mecasermin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                                                                                                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0081             | 16th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 14/12/2023 | n/a        |             | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Increlex should be maintained. |
| II/0080            | Update of sections 4.2, 4.6, and 4.8 of the SmPC in order to modify administration instructions recommendation regarding the monitoring of pre- prandial blood glucose in pre-prandial condition and in case of symptoms and to prevent the risk of lipohypertrophy, delete wording in the pregnancy section and update on number of patients with severe primary IGFD based on the cumulative review of safety database, scientific literature and clinical trials data. The Package Leaflet is updated accordingly. The RMP version 14.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/10/2023 | 31/10/2024 | SmPC and PL |                                                                                                                                                                                                                                                                   |
| PSUSA/1942/ 202208 | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16/03/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |
| S/0078             | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 15/12/2022 | n/a        |             |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| II/0077/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/09/2022   | n/a   |      |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------|
|             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion non-significant in-process test |              |       | of a |
| II/0076     | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/06/2022   | n/a   |      |

<div style=\"page-break-after: always\"></div>

| PSUSA/1942/ 202108   | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                                                                                                                       | 07/04/2022   | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0075/G            | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol                          | 06/01/2022   | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| S/0070               | Annual re-assessment.                                                                                                                                                                                                                                                                          | 16/12/2021   | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0067              | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 11/11/2021   | 08/07/2022 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0071              | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                      | 09/11/2021   | 08/07/2022 | SmPC and PL     | To update the shelf-life from '36 months' to '60 months' in section 6.3 of the Summary of Product Characteristics (SmPC); To update the visual description of the appearance of the product in section 3 of the SmPC and in section 6 of the Patient Information Leaflet (PIL) to comply with section 3.2.P.5.1 Specification(s); To update section 4.4 of the SmPC and section 2 of the PIL with regards to sodium content according to the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                 | human use' (SANTE-2017-11668).   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------|
| IB/0072/G   | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                    | 27/10/2021 | n/a        |                 |                                  |
| IAIN/0073/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 12/10/2021 | 08/07/2022 | Annex II and PL |                                  |
| IB/0069/G   | This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.I.b.1.c - Change in the specification parameters        | 06/10/2021 | n/a        |                 |                                  |

<div style=\"page-break-after: always\"></div>

|           | - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                          |            |            |      | material/intermediate/reagent   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------|
| II/0068/G | This was an application for a group of variations. B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.b.1.c - Replacement or addition of a | 22/07/2021 | 08/07/2022 | SmPC | manufacturing site              |

<div style=\"page-break-after: always\"></div>

|                    | manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0064             | 13th annual re-assessment                                                                                                                                                                                                                                                                                                | 25/02/2021 | 21/04/2021 | Annex II and PL | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Increlex should be maintained. The description of the non-interventional PASS has been reworded and the timeline for completion of the final study report was extended to 2030. |
| PSUSA/1942/ 202008 | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                                                                                                                                                 | 09/04/2021 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0066            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                            | 04/03/2021 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/1942/ 201908 | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                                                                                                                                                 | 12/03/2020 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                  |
| S/0061             | 12th annual re-assessment                                                                                                                                                                                                                                                                                                | 30/01/2020 | n/a        |                 | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Increlex should be maintained.                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IA/0063   | B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                                                                                                                                                                                                         | 16/01/2020   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0060   | Update of sections 4.1, 4.2, 4.3, 4.4, 4.8 and 4.9 of the SmPC in order to update the safety information on benign or malignant neoplasia based on the EU Registry Study, the Ipsen global safety database and literature review. The Package Leaflet is updated accordingly. The MAH also submitted the updated RMP version 11.3. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 14/11/2019   | 16/12/2019 | SmPC, Annex II and PL | Mecasermin should only be used in the treatment of confirmed severe primary IGF-1 deficiency and the maximum dose of 0.12 mg/kg given twice daily should not be exceeded. Increlex is contraindicated in children and adolescents with active or suspected neoplasia, or any condition or medical history which increases the risk of benign or malignant neoplasia. There have been post-marketing reports of both benign and malignant neoplasms in children and adolescents who have received treatment with Increlex. These cases represented a variety of different malignancies and included rare malignancies usually not seen in children. Current knowledge of IGF-1 biology suggests that IGF-1 plays a role in malignancies in all organs and tissues. Physicians should therefore be vigilant of any symptoms of potential malignancy. If benign or malignant neoplasia develops, Increlex treatment should be discontinued and appropriate expert medical care sought. 'Benign and malignant neoplasms' have been introduced in section 4.8 of the SmPC, with frequency 'not known'. In case of an acute or a chronic overdose, Increlex must be discontinued immediately. If Increlex is restarted, the dose should not exceed the recommended daily dosage. |
| II/0059   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/10/2019   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                    | of studies to the competent authority                                                                                                                                                                                                                                  |            |     |                                                                                                                                                                                                                                                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0055             | 11th annual re-assessment                                                                                                                                                                                                                                              | 26/04/2019 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Increlex should be maintained. |
| IB/0057            | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                            | 28/03/2019 | n/a |                                                                                                                                                                                                                                                                   |
| PSUSA/1942/ 201808 | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                                                                                               | 14/03/2019 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |
| IB/0058            | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 12/03/2019 | n/a |                                                                                                                                                                                                                                                                   |
| IB/0053            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                           | 09/10/2018 | n/a |                                                                                                                                                                                                                                                                   |
| IB/0054/G          | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                        | 30/08/2018 | n/a |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                    | re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol   |            |            |      |                                                                                                                                                                                      |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1942/ 201708 | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                               | 12/04/2018 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                    |
| S/0050             | Annual re-assessment.                                                                                                                                                                                  | 22/02/2018 | n/a        |      |                                                                                                                                                                                      |
| IB/0052            | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                 | 07/02/2018 | n/a        |      |                                                                                                                                                                                      |
| IB/0048            | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                    | 23/11/2017 | n/a        |      |                                                                                                                                                                                      |
| IB/0049            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                       | 08/11/2017 | n/a        |      |                                                                                                                                                                                      |
| IB/0047            | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                 | 16/10/2017 | n/a        |      |                                                                                                                                                                                      |
| II/0044/G          | This was an application for a group of variations. C.I.4 - Update of section 4.4 of the SmPC in order to                                                                                               | 14/09/2017 | 20/09/2018 | SmPC | Update of section 4.4 of the SmPC to indicate that patients that have high blood values of IGF-1 after injection, or who fail to show a growth response without any identified cause |

<div style=\"page-break-after: always\"></div>

|         | update the warning regarding antibody response to injected IGF-1. C.I.11.b - Submission of an updated RMP version 9.3. As part of this update, the risks of cardiomegaly and scoliosis were changed from important potential risks to important identified risks. In addition, wording regarding antibody testing was amended in Physician educational brochure as per update of the SmPC linked to antibody response to injected IGF-1. In addition, the marketing authorisation holder took the opportunity to introduce editorial changes in the SmPC and Annex IIIA. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   |            |            |                                  | may be linked the production of anti-IGF-1 IgEs, sustaining antibodies or neutralizing antibodies respectively. An updated RMP has been submitted as part of this application.                                                                                         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0042  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/04/2017 | 16/06/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Increlex in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0040 | Update of section of 4.1 of the SmPC in order to re-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21/04/2017 | 02/06/2017 | SmPC                             | The current indication reflected in section 4.1 for Increlex                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | word the recommendation to confirm diagnosis with an IGF-1 generation test used for diagnosis of Severe Primary IGFD. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |          | states that it is recommended to confirm the diagnosis of severe primary IGF-1 deficiency (SPIGFD) by conducting an IGF-1 generation test. Section 4.1 of the SmPC is being updated as part of this procedure in relation to the diagnosis to 'In some cases, when deemed necessary, the physician may decide to assist in the diagnosis by performing an IGF-I generation test'. Following a literature review, IGFGT test did not prove to be a strong predictor of growth response in GH deficiency. However, the test may be used to assist the diagnosis. Therefore, the clinician decides whether there is a need to use the IGF-1 generation test to confirm the diagnosis of severe primary IGFD.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0046/G | This was an application for a group of variations.                                                                                                                                                                                        | 30/03/2017 | 02/06/2017 | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| the AS - The change refers manufacture of a biological/immunological which may have a significant product and is not related B.I.a.4.z - Change to in-process applied during the manufacture variation B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.f - Change in the and/or limits of an AS, material/intermediate/reagent approved specifications B.I.b.1.z - Change in the and/or limits of an AS, material/intermediate/reagent B.I.b.2.a - Change in test starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in test starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in test starting material/reagent/intermediate changes to an approved B.I.d.1.c - Stability of AS period/storage period or   | to an approved stability   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|

<div style=\"page-break-after: always\"></div>

| PSUSA/1942/ 201608   | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/03/2017   | n/a   | PRAC Recommendation - maintenance   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| S/0041               | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/02/2017   | n/a   |                                     |
| IA/0045/G            | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 16/12/2016   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

|           | packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| IB/0039/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 06/10/2016 | n/a | control/testing |
| II/0037/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test                                                                                                                                                                                                                                                                                                                      | 26/05/2016 | n/a |                 |

<div style=\"page-break-after: always\"></div>

|                    | method or a method using a biological reagent for a biological AS B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol   |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0035             | Annual re-assessment.                                                                                                                                                                                                                                                                                                                        | 25/02/2016 | 08/04/2016 | Annex II | The CHMP considered that the benefit/risk profile of the medicinal product remains positive in the approved indication and concluded that Marketing Authorisation of Increlex should be varied. The specific obligation S0 001 is considered fulfilled and the Annex II is amended accordingly. In addition updated information related to S0 002 is introduced. The remaining Specific obligation (SO 002) needs to be fulfilled and the Marketing Authorisation will continue to be reviewed annually. |
| PSUSA/1942/ 201508 | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                                                                                                                                                                     | 17/03/2016 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0038            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                | 29/01/2016 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| PSUSA/1942/ 201408 | Periodic Safety Update EU Single assessment - mecasermin                                                                                                                                                                                                                                                                                     | 26/03/2015 | 27/05/2015 | SmPC     | Please refer to Increlex PSUSA-1942-201408 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation                                                                                                                                                                                                                                                                                                                                               |
| S/0032             | 7th Annual Re-assessment                                                                                                                                                                                                                                                                                                                     | 26/02/2015 | 05/05/2015 | Annex II | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                       | submitted by the MAH on the benefit/risk profile of the medicinal product, remains favourable and concluded that Marketing Authorisation of Increlex should be varied. Minor changes are implemented to bring the annex II in line with the QRD template, introducing dues date for the specific obligations.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028   | Update of section 4.8 of the SmPC in line with the updated Company Core Safety Information, and upon request by PRAC following the assessment of PSUV/0026, and section 5.1 of the SmPC with the results from the integrated Clinical Study Report of study 1419. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 9.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 23/04/2015 | 08/04/2016 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                 |
| IAIN/0034 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                               | 02/02/2015 | n/a        |                       |                                                                                                                                                                                                                                                                                                                 |
| II/0031   | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/01/2015 | n/a        |                       |                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| IAIN/0030   | C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring                                            | 15/08/2014   | 05/05/2015   | SmPC and PL   |                                   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------------------------------|
| IAIN/0029   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                         | 01/07/2014   | n/a          |               |                                   |
| S/0024      | Annual re-assessment.                                                                                                                                                                                                   | 25/04/2014   | n/a          |               |                                   |
| N/0027      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                        | 23/04/2014   | 05/05/2015   | PL            |                                   |
| PSUV/0026   | Periodic Safety Update                                                                                                                                                                                                  | 10/04/2014   | n/a          |               | PRAC Recommendation - maintenance |
| IAIN/0025   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                         | 10/12/2013   | n/a          |               |                                   |
| N/0022      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                        | 07/11/2013   | 05/05/2015   | PL            |                                   |
| IB/0023/G   | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of | 21/10/2013   | n/a          |               |                                   |

<div style=\"page-break-after: always\"></div>

|         | the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0021  | 5th Annual Re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/02/2013 | 22/04/2013 | Annex II                  | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0020 | Update of SmPC section 4.8, upon request by the CHMP following assessment of PSUR 7, to include the ADR 'alopecia'. The Package Leaflet has been updated accordingly. In addition, the MAH has taken the opportunity to update the contact details of the local representatives in the Package Leaflet. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 19/07/2012 | 30/08/2012 | SmPC and PL               | A total of 43 cases have been received involving 'alopecia' and/or 'hair texture changes' (all non-serious events). A very small number of these cases reported confounding factors. However, in these cases, a causal relationship with mecasermin could not be excluded. In three cases reporting 'alopecia', mecasermin treatment was discontinued due to the event. Two cases involving 'alopecia' reported that the patient recovered after the mecasermin dose was reduced, demonstrating a dose- response relationship. One case involving 'alopecia' reported that the patient recovered despite no action being taken with mecasermin treatment. In addition, the reporting rate meets the Company's internal threshold for disproptionate reporting. Although very little can be found in the literature regarding IGF-1 and adverse events relating to hair, it is possible that IGF-1 treatment may have an impact on hair growth. |
| R/0019  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/05/2012 | 03/08/2012 | SmPC, Annex II, Labelling | Based on the CHMP review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the CHMP considers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and PL   |
|----------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |          | positive.                                                                                                                                                                                                                                                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0018    | 4th Annual Re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/05/2012 | 03/08/2012 | Annex II | The CHMP, having reviewed the level of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable. |
| II/0017/G | This was an application for a group of variations. - Change in test procedure - Addition of a specification parameter - Addition of a bioassay working cell bank - Changes to in-process controls - Change of name of a QC site B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS B.I.a.4.d - Change to in-process tests or limits | 23/06/2011 | 23/06/2011 |          |                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | of the approved in-process test limits, which may have a significant effect on the overall quality of the AS A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|
| II/0016/G | This was an application for a group of variations. - Change in the manufacturing site of the active substance - Changes to manufacturing process - Addition of five raw material QC testing sites and one release testing site - Change in the specifications of raw materials and reagents - Change in analytical procedures - Deletion of a manufacturing site B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.1.z - Change in the manufacturer of AS or of a | 19/05/2011 | 17/06/2011 | Annex II |

<div style=\"page-break-after: always\"></div>

|        | variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS A.7 - Administrative change - Deletion of   |            |            |                        |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| S/0015 | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/03/2011 | 16/06/2011 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| II/0014   | Update of Annex II and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/12/2010   | 01/02/2011   | Annex II and PL       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|
| II/0013   | Update of sections 4.4 and 4.8 of the SPC, upon request by CHMP following the assessment of PSUR 4, with further information regarding local allergic reactions at the injection site and cases of systemic hypersensitivity. The Package Leaflet has been updated accordingly. Consequently, annex IIB - conditions or restrictions with regard to the safe and effective use of the medicinal product - has been updated to specify that the existing paragraph providing information on treatment interruption and need of medical attention refers to systemic allergic reactions. In addition, the MAH takes the opportunity to implement minor editorial changes in the annexes and to update the name of the Czech local representative in the Package Leaflet. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 24/06/2010   | 28/07/2010   | SmPC, Annex II and PL |
| S/0012    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/01/2010   | 30/03/2010   | Annex II              |

<div style=\"page-break-after: always\"></div>

| II/0011   | Change(s) to the manufacturing process for the finished product                                                                                                                      | 19/11/2009   | 25/11/2009   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0010    | Transfer of Marketing Authorisation                                                                                                                                                  | 19/06/2009   | 14/07/2009   | SmPC, Annex II, Labelling and PL | Transfer of Marketing Authorisation for Increlex from Tercica Europe Ltd. to Ipsen Pharma.                                                                                                                                                                                                                                                                                                                              |
| IA/0008   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                   | 24/03/2009   | n/a          | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0009   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product | 23/03/2009   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0006   | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                           | 17/03/2009   | n/a          | SmPC                             |                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0007   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product | 17/03/2009   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                         |
| S/0003    | Annual re-assessment.                                                                                                                                                                | 25/09/2008   | 20/11/2008   | Annex II                         | Based on the available data, the safety profile of Increlex has not changed from the time of the marketing authorisation and no new adverse events have been described during this first year. Furthermore, none of the additional information provided as part of the post-authorisation specific obligations or follow-up measures in clinical and quality data suggest any change to the safety profile of Increlex. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                          |            |            |                        | Most of the post-authorisation commitments are still ongoing and the closely reporting will continue during this year. Overall, the CHMP considered that the MA for Increlex should remain under exceptional circumstances in view of the pending Specific Obligations.   |
|---------|----------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0005 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                 | 15/09/2008 | n/a        |                        |                                                                                                                                                                                                                                                                           |
| IA/0004 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing         | 15/09/2008 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                           |
| II/0002 | Update of Detailed Description of the Pharmacovigilance System (DDPS) Update of DDPS (Pharmacovigilance) | 26/06/2008 | 29/07/2008 | Annex II               | In accordance with Article 8(3)(ia) of directive 2001/83/EC as amended, the MAH submitted a Detailed Description of the Pharmacovigilance System (DDPS) for Increlex, with their Marketing Authorisation Application. This is now being updated.                          |
| IA/0001 | IA_01_Change in the name and/or address of the marketing authorisation holder                            | 23/11/2007 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                           |